HPV vaccines

Price for one auto-disable (AD) syringe and needle

• As of October 2025, the UNICEF procurement price for 2026 ranges from US$ 0.023 to US$ 0.046, depending on supplier and product. ^{Go to footnote 11}
• The 2026 PAHO Revolving Fund for Access to Vaccines price ranges from US$ 0.03 to US$ 0.04, depending on supplier and product.^{Go to footnote 22}

Price for one 5-litre safety box 

• The UNICEF procurement price for 2026 ranges from US$ 0.375 to US$ 0.86, depending on supplier and product.^{Go to footnote 33}
• The 2026 PAHO Revolving Fund for Access to Vaccines prices ranges from US$ 0.41 to US$ 0.47.^{Go to footnote 22}

Each 5-litre safety box can hold around 100 syringes.

As of June 2026, the UNICEF price per dose for countries eligible for Gavi pricing ranges from US$ 2.80 for a bivalent vaccine, single dose vial (Walvax) to US$ 5.18 for a bivalent vaccine, two dose vial (GSK), depending on the supplier, valency and presentation.^{Go to footnote 44}

For different groupings of Middle Income Countries (MIC), the UNICEF price per dose ranges from US$ 2.90 for a bivalent vaccine, single dose vial (Cecolin) to US$ 33.25 for a nonavalent vaccine, single dose vial (MSD), depending on supplier, valency and presentation.^{Go to footnote 44}

UNICEF prices are subject to change. The latest HPV vaccine price information is available from UNICEF Supply Division.^{Go to footnote 44} 

Users are encouraged to confirm current prices by contacting UNICEF Supply Division.

The 2026 PAHO Revolving Fund for Access to Vaccines pricelist reports a price per dose ranging from US$ 2.90 for the bivalent vaccine to US$ 14.99 for the nonavalent vaccine.^{Go to footnote 55}

The June 2026 US CDC pricelist reports a price per dose of US$ 275.013-329.090 for the nonavalent HPV vaccine (Merck/MSD) in the United States.^{Go to footnote 66}

Among self-procuring MICs, county-reported prices for 2025 per dose range from US$ 9.50 to US$ 11.53 for bivalent, US$ 10.55 to US$ 118.83 for the quadrivalent and US$ 32.7 and US$ 119.47 for the nonavalent vaccines.^{Go to footnote 77}

The cost of vaccine delivery can vary greatly depending on the strategies, financing elements (e.g., vaccine procurement and delivery costs), and the country context. 

A six-country study published in November 2023 (Ethiopia, Guyana, Rwanda, Senegal, Sri Lanka, and Uganda) reported the financial cost per dose from approximately US$ 1.50 to US$ 5.50, and economic costs ranging from US$ 2.50 to US$ 7.50 per dose. These differences were influenced by factors such as service delivery strategies, the number of doses administered per health facility, and the intensity of program activities. Health facility activities and associated expenditures accounted for the largest proportion of the economic cost per dose. Health worker and non-health worker time were also substantial cost components, regardless of the operational context.^{Go to footnote 88}

A 2020 study in Zambia estimated the financial cost of school-based delivery at US$ 12.40 per Fully Immunised Child (cost of vaccine is the co-financing portion only).^{Go to footnote 99}

A 2024 five country study (Ethiopia, Guyana, Rwanda, Sri Lanka, and Uganda) modelled the financial cost of vaccine procurement and delivery per adolescent receiving the full schedule as ranging from US$ 9.64 (Sri Lanka) to US$ 23.43 (Guyana) using a 2-dose schedule. The cost decreased to US$ 4.84 and US$ 12.34, respectively, under a single-dose schedule, reflecting savings up to 50%. For economic costs, the range for a single-dose schedule was US$ 7.86 (Rwanda) to US$ 28.53 (Guyana).^{Go to footnote 1010}

Global cost-effectiveness analysis suggests that vaccinating pre-adolescent girls is usually cost-effective for cervical cancer prevention, particularly in resource-constrained settings where screening and other cervical cancer prevention and control measures often have limited coverage. At 2020 prices for the bivalent and quadrivalent vaccines, girls-only vaccination was cost-effective (compared with no vaccination), irrespective of the schedule or vaccine used.^{Go to footnote 1111, Go to footnote 1212}

HPV vaccination is generally cost-effective or even cost-saving in both high- and low-income countries, especially when targeting girls 9–14 years of age. The mean incremental cost-effectiveness ratio (ICER) for HPV vaccination globally is estimated at US$ 4 217 per disability-adjusted life year (DALY) averted, with much lower ICERs in regions with high cervical cancer burden, such as Sub-Saharan Africa and South Asia.^{Go to footnote 1313} In Latin America, most studies found HPV vaccination to be cost-saving or cost-effective, with mean ICERs ranging from I$ 358 to I$ 3 804 depending on the vaccine type and study parameters.^{Go to footnote 1414}   

Cost–effectiveness varies considerably by several factors, including, the burden of disease, vaccination coverage, vaccine price, delivery costs, delivery approaches, and schedules. Caution is recommended when comparing estimates of cost-effectiveness for different interventions evaluated by different methods and in different contexts (e.g., with different concurrent health interventions and standards of care).

Gavi opened a funding window for HPV vaccines in 2013.HPV vaccine introduction is supported by the guaranteed vaccine budget. The calculations of the budget amount are based on adoption of a single dose schedule and lower cost products.

All Gavi-eligible and Catalytic Phase countries that have not yet introduced HPV vaccine into their national vaccination schedule are eligible for support. For these countries, that have not yet introduced HPV vaccination into their national EPI schedule, Gavi supports routine HPV vaccine introduction calculated on a single-age cohort of girls aged between 9–14 years.

Introductions can be combined with a one-time multi-age cohort (MAC) catch-up campaign for girls up to age 14 to maximise impact in the first year. As of 2027, co-financing of MAC doses will be required.

For countries with existing HPV vaccination programmes, Gavi provides support for HPV optimisation, which may include switching vaccine product or schedule. 

Either a one-dose or two-dose HPV vaccination schedule can be selected, however the guaranteed vaccine budget is calculated based on a single-dose schedule. 

Countries in the Catalytic Phase are eligible for vaccine support to cover 50% of the routine immunisation target cohort; these countries are not eligible for MAC catch-up campaign funding.^{Go to footnote 1515}